1
|
Sreedharan L, Mayne GC, Watson DI, Bright T, Lord RV, Ansar A, Wang T, Kist J, Astill DS, Hussey DJ. MicroRNA profile in neosquamous esophageal mucosa following ablation of Barrett’s esophagus. World J Gastroenterol 2017; 23:5508-5518. [PMID: 28852310 PMCID: PMC5558114 DOI: 10.3748/wjg.v23.i30.5508] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Revised: 05/18/2017] [Accepted: 07/04/2017] [Indexed: 02/06/2023] Open
Abstract
AIM To investigate the microRNA expression profile in esophageal neosquamous epithelium from patients who had undergone ablation of Barrett’s esophagus.
METHODS High throughput screening using TaqMan® Array Human MicroRNA quantitative PCR was used to determine expression levels of 754 microRNAs in distal esophageal mucosa (1 cm above the gastro-esophageal junction) from 16 patients who had undergone ablation of non-dysplastic Barrett’s esophagus using argon plasma coagulation vs pretreatment mucosa, post-treatment proximal normal non-treated esophageal mucosa, and esophageal mucosal biopsies from 10 controls without Barrett’s esophagus. Biopsies of squamous mucosa were also taken from 5 cm above the pre-ablation squamo-columnar junction. Predicted mRNA target pathway analysis was used to investigate the functional involvement of differentially expressed microRNAs.
RESULTS Forty-four microRNAs were differentially expressed between control squamous mucosa vs post-ablation neosquamous mucosa. Nineteen microRNAs were differentially expressed between post-ablation neosquamous and post-ablation squamous mucosa obtained from the more proximal non-treated esophageal segment. Twelve microRNAs were differentially expressed in both neosquamous vs matched proximal squamous mucosa and neosquamous vs squamous mucosa from healthy patients. Nine microRNAs (miR-424-5p, miR-127-3p, miR-98-5p, miR-187-3p, miR-495-3p, miR-34c-5p, miR-223-5p, miR-539-5p, miR-376a-3p, miR-409-3p) were expressed at higher levels in post-ablation neosquamous mucosa than in matched proximal squamous and healthy squamous mucosa. These microRNAs were also more highly expressed in Barrett’s esophagus mucosa than matched proximal squamous and squamous mucosa from controls. Target prediction and pathway analysis suggests that these microRNAs may be involved in the regulation of cell survival signalling pathways. Three microRNAs (miR-187-3p, miR-135b-5p and miR-31-5p) were expressed at higher levels in post-ablation neosquamous mucosa than in matched proximal squamous and healthy squamous mucosa. These miRNAs were expressed at similar levels in pre-ablation Barrett’s esophagus mucosa, matched proximal squamous and squamous mucosa from controls. Target prediction and pathway analysis suggests that these microRNAs may be involved in regulating the expression of proteins that contribute to barrier function.
CONCLUSION Neosquamous mucosa arising after ablation of Barrett’s esophagus expresses microRNAs that may contribute to decreased barrier function and microRNAs that may be involved in the regulation of survival signaling pathways.
Collapse
|
2
|
Levert-Mignon A, Bourke MJ, Lord SJ, Taylor AC, Wettstein AR, Edwards M, Botelho NK, Sonson R, Jayasekera C, Fisher OM, Thomas ML, Macrae F, Hussey DJ, Watson DI, Lord RV. Changes in gene expression of neo-squamous mucosa after endoscopic treatment for dysplastic Barrett's esophagus and intramucosal adenocarcinoma. United European Gastroenterol J 2017; 5:13-20. [PMID: 28405317 DOI: 10.1177/2050640616650794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/08/2015] [Accepted: 04/27/2016] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND Endoscopic therapy, including by radiofrequency ablation (RFA) or endoscopic mucosal resection (EMR), is first line treatment for Barrett's esophagus (BE) with high-grade dysplasia (HGD) or intramucosal cancer (IMC) and may be appropriate for some patients with low-grade dysplasia (LGD). OBJECTIVE The purpose of this study was to investigate the molecular effects of endotherapy. METHODS mRNA expression of 16 genes significantly associated with different BE stages was measured in paired pre-treatment BE tissues and post-treatment neo-squamous biopsies from 36 patients treated by RFA (19 patients, 3 IMC, 4 HGD, 12 LGD) or EMR (17 patients, 4 IMC, 13 HGD). EMR was performed prior to RFA in eight patients. Normal squamous esophageal tissues were from 20 control individuals. RESULTS Endoscopic therapy resulted in significant change towards the normal squamous expression profile for all genes. The neo-squamous expression profile was significantly different to the normal control profile for 11 of 16 genes. CONCLUSION Endotherapy results in marked changes in mRNA expression, with replacement of the disordered BE dysplasia or IMC profile with a more "normal" profile. The neo-squamous mucosa was significantly different to the normal control squamous mucosa for most genes. The significance of this finding is uncertain but it may support continued endoscopic surveillance after successful endotherapy.
Collapse
Affiliation(s)
- Angelique Levert-Mignon
- Gastroesophageal Cancer Research Program, St Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia
| | - Michael J Bourke
- Department of Gastroenterology and Hepatology, Westmead Hospital, Westmead, NSW, Australia
| | - Sarah J Lord
- Gastroesophageal Cancer Research Program, St Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia; School of Medicine, University of Notre Dame, Sydney, NSW, Australia
| | - Andrew C Taylor
- Department of Gastroenterology, St Vincent's Hospital, Melbourne, VIC, Australia
| | - Antony R Wettstein
- Diagnostic Endoscopy Centre, St Vincent's Clinic, Sydney, NSW, Australia
| | - Melanie Edwards
- School of Medicine, University of Notre Dame, Sydney, NSW, Australia; Department of Histopathology, Douglass Hanly Moir Pathology, Sydney, NSW Australia
| | - Natalia K Botelho
- Gastroesophageal Cancer Research Program, St Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia
| | - Rebecca Sonson
- Department of Gastroenterology and Hepatology, Westmead Hospital, Westmead, NSW, Australia
| | - Chatura Jayasekera
- Department of Gastroenterology, St Vincent's Hospital, Melbourne, VIC, Australia
| | - Oliver M Fisher
- Gastroesophageal Cancer Research Program, St Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia
| | - Melissa L Thomas
- Gastroesophageal Cancer Research Program, St Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia; School of Medicine, University of Notre Dame, Sydney, NSW, Australia
| | - Finlay Macrae
- Department of Colorectal Medicine and Genetics, The Royal Melbourne Hospital, Parkville, VIC, Australia; Department of Medicine, The University of Melbourne, Parkville, VIC, Australia
| | - Damian J Hussey
- Department of Surgery, Flinders University, Flinders Medical Centre Bedford Park, SA, Australia; Flinders Centre for Cancer Prevention and Control, Flinders University, Bedford Park, SA, Australia
| | - David I Watson
- Department of Surgery, Flinders University, Flinders Medical Centre Bedford Park, SA, Australia; Flinders Centre for Cancer Prevention and Control, Flinders University, Bedford Park, SA, Australia
| | - Reginald V Lord
- Gastroesophageal Cancer Research Program, St Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia; School of Medicine, University of Notre Dame, Sydney, NSW, Australia; Diagnostic Endoscopy Centre, St Vincent's Clinic, Sydney, NSW, Australia
| |
Collapse
|